SCHEMBL4687447

SCHEMBL4687447

Cc1ccc(-c2ccoc2C(=O)NC2CCN(CCC3(CCCC(=O)O)CCCCC3)CC2)nc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.34
ADRA1D P25100 2/20 0.34
ADRA1A P35348 2/20 0.34
ADRA1B P35368 2/20 0.34
HPGDS O60760 2/20 0.33
CARM1 Q86X55 1/20 0.33
PRMT6 Q96LA8 1/20 0.33
MAPK14 Q16539 2/20 0.33
DRD2 P14416 1/20 0.33
HTR2A P28223 1/20 0.33
DRD3 P35462 1/20 0.33
P2RX3 P56373 1/20 0.33
P2RX2 Q9UBL9 1/20 0.33
P2RX7 Q99572 1/20 0.33
AXL P30530 1/20 0.32
FLT3 P36888 1/20 0.32
TYRO3 Q06418 1/20 0.32
MERTK Q12866 1/20 0.32
GAS6 Q14393 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4686523 0.93 PDE10A (0.37) PDE10AL3MBTL1HPGDSMAPK14DRD2
SCHEMBL1847387 0.92 PDE10A (0.40) PDE10AL3MBTL1HPGDSCARM1PRMT6
SCHEMBL4690502 0.92 PDE10A (0.35) PDE10AL3MBTL1ADRA1DADRA1AADRA1B
SCHEMBL4690005 0.92 PDE10A (0.40) PDE10AL3MBTL1HPGDSCARM1PRMT6
SCHEMBL4686983 0.91 PDE10A (0.41) PDE10AL3MBTL1HPGDSCARM1PRMT6
SCHEMBL5113065 0.91 PDE10A (0.37) PDE10AL3MBTL1ADRA1DADRA1AADRA1B
SCHEMBL4691747 0.90 PDE10A (0.37) PDE10AL3MBTL1ADRA1DADRA1AADRA1B
SCHEMBL4687145 0.90 PDE10A (0.39) PDE10AL3MBTL1HPGDSCARM1PRMT6
SCHEMBL4686652 0.88 PDE10A (0.38) PDE10AL3MBTL1HPGDSCARM1PRMT6
SCHEMBL4693190 0.88 L3MBTL1 (0.39) L3MBTL1ADRA1DADRA1AADRA1BCARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1443046-B1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME KYORIN SEIYAKU KK (JP) 2008-12-17 EP disclosed
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. 2008-08-14 US disclosed
US-7375115-B2 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-05-20 US disclosed
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2005-04-21 US disclosed
EP-1443046-A1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME Kyorin Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same CYP4F2, CYP1A2, CYP4B1 PDE10A 317/4885L3MBTL1 4882/4885ADRA1D 670/4885
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same OPRM1, OPRD1, HRH4 PDE10A 2390/4885L3MBTL1 3273/4885ADRA1D 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.